A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (Dragon)

This is a multi-center, open-label, Phase 1, FIH, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and efficacy of SRK-181 administered by IV infusion alone and in combination with an anti-PD-(L)1 therapy (specifically anti- PD-1 or PD-L1 therapies) in adult patients with locally advanced or metastatic solid tumors.